| Previous close | 0.875 |
| Open | 0.875 |
| Bid | 0.000 x 130000000 |
| Ask | 0.000 x 30000000 |
| Day's range | 0.870 - 0.895 |
| 52-week range | 0.557 - 1.725 |
| Volume | 2,788,385 |
| Avg. volume | 7,198,526 |
| Market cap | 23.15M |
| Beta | N/A |
| PE ratio (TTM) | -∞ |
| EPS (TTM) | -0 |
| Earnings date | 22 Feb 2017 - 27 Feb 2017 |
| Dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.02 |
PNT737 is being investigated in two recently initiated Phase 1 clinical trials, currently sponsored and managed by the Cancer Research UK Centre for Drug Development, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.